In addition to the two AEB Series reviews of medication treatments for addiction, five studies examine use and prescribing of various other medications. In a national data analysis, T. Scott Stroup, M.D., M.P.H., and colleagues found that clozapine, the only antipsychotic approved for treatment-resistant schizophrenia, is rarely used and that geographic factors appear to play a role (page 186). In a related commentary, Martha Sajatovic, M.D., joins with Stroup and colleagues in calling on clinicians, care systems, policy makers, and consumers to implement ways to reverse clozapine’s underuse (page 135). Ana R. Quiñones, Ph.D., and colleagues found that among more than 62,000 veterans with chronic depression, those from most minority groups were significantly less likely than white veterans to receive adequate antidepressant treatment. However, findings for psychotherapy were quite different (page 193). Gail A. Edelsohn, M.D., M.S.P.H., and coauthors examined the appropriateness of psychotropic prescribing for Medicaid-enrolled children with both an intellectual disability and a mental disorder (page 201). Liang-Jen Wang, M.D., M.P.H., and colleagues found high and rising rates of anxiolytic-hypnotic use in the Taiwanese population (page 208). Finally, despite generally poor adherence to antidiabetic medications among Texas Medicaid patients, Pooja R. Desai, M.S., and colleagues found significantly better adherence among patients who were also taking antipsychotics, suggesting that the coexistence of a mental illness does not compromise—and may even improve—outcomes of chronic comorbid conditions (page 215).